Clinical and economic impact of adverse drug reactions in hospitalized patients

被引:138
|
作者
Suh, DC
Woodall, BS
Shin, SK
Hermes-De Santis, ER
机构
[1] Rutgers State Univ, Coll Pharm, Piscataway, NJ 08854 USA
[2] UMDNJ Robert Wood Johnson Univ Hosp, Drug Informat Serv, New Brunswick, NJ USA
关键词
adverse drug reactions; costs;
D O I
10.1345/aph.10094
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To identify the classes of drugs that most commonly cause adverse drug reactions (ADRs) and the characteristics of these ADRs and to determine the economic impact of ADRs on patients' length of stay and hospitalization costs. METHODS: Data on ADRs from patients admitted to a hospital in New Jersey were collected, studied, and analyzed over a five-month period. To determine the economic impact of ADRs, patients who experienced ADRs during hospitalization were matched to controls. Each ADR was rated with regard to is severity, the patients' outcomes were determined, and specific classes of medications were identified as particularly causative of ADRs. RESULTS: A total of 196 patients experienced ADRs; 131 of these individuals were matched with 1338 patients who did not experience an ADR, based on their diagnosis-related group code. The leading causal drugs according to therapeutic class were antiinfective (17%), cardiovascular (17%), antineoplastic (15%), and analgesics/antiinflammatory agents (15%). The organ systems most often affected were gastrointestinal (24%), dermatologic (19%), and immune systems (15%). The mean length of stay per patient differed significantly between the ADR case group and matched control group (10.6 vs. 6.8 d; p = 0.003), as did the total hospitalization cost ($22 775 vs. $17 292; p = 0.025). CONCLUSIONS: Length of hospital stay and total hospitalization costs were significantly higher for patients experiencing ADRs than those who did not experience ADRs. ADR reporting systems in hospitals need to be changed and strengthened to decrease the incidence of avoidable reactions.
引用
收藏
页码:1373 / 1379
页数:7
相关论文
共 50 条
  • [21] MONITORING OF ADVERSE DRUG REACTIONS IN HOSPITALIZED PATIENTS IN CARDIOLOGY CENTER
    Mugosa, S.
    Todorovic, Z.
    Duborija-Kovacevic, N.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 87 - 87
  • [22] Factors Causing or Contributing to Adverse Drug Reactions in Hospitalized Patients
    Bucsa, Camelia D.
    Farcas, Andreea M.
    Bojita, Marius T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 223 - 223
  • [23] Risk factors for severe adverse drug reactions in hospitalized patients
    Petrovic, Nemanja Z.
    Pejcic, Ana V.
    Milosavljevic, Milos N.
    Jankovic, Slobodan M.
    OPEN MEDICINE, 2025, 20 (01):
  • [24] DERMATOLOGIC ADVERSE DRUG-REACTIONS IN HOSPITALIZED-PATIENTS
    STEWART, RB
    MAY, FE
    CULLEN, SI
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1979, 36 (05): : 609 - 612
  • [25] Adverse Drug Reactions in Hospitalized Women
    Demler, Tammie Lee
    US PHARMACIST, 2020, 45 (09) : HS2 - HS7
  • [26] Clinical and economic impact of hyponatremia in hospitalized patients
    Callahan, M. A.
    ETHNICITY & DISEASE, 2007, 17 (03) : S22 - S22
  • [27] ECONOMIC IMPACT OF ADVERSE DRUG REACTIONS: A PUBMED BASED STUDY
    Bhat, B.
    Udupa, N.
    VALUE IN HEALTH, 2016, 19 (07) : A486 - A486
  • [28] Readmissions and adverse drug reactions in internal medicine:: the economic impact
    Dormann, H
    Neubert, A
    Criegee-Rieck, M
    Egger, T
    Radespiel-Tröger, M
    Azaz-Livshits, T
    Levy, M
    Brune, K
    Hahn, EG
    JOURNAL OF INTERNAL MEDICINE, 2004, 255 (06) : 653 - 663
  • [29] The economic impact of serious adverse drug reactions (ADRs) to anticonvulsants
    Schlienger, RG
    Knowles, SR
    Shear, NH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI3 - PI3
  • [30] Cardiovascular drug adverse reactions in hospitalized patients in cardiac care unit
    Karimzadeh, Iman
    Namazi, Soha
    Shalviri, Gloria
    Gholami, Kheirollah
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 5 (04): : 493 - 499